Cytori Therapeutics probably ranks somewhere near the top of any list of the world's most innovative medical technology companies--or at least a list of its boldest. As CEO Christopher J. Calhoun explains, the company aims to do nothing less than revolutionize health care by leading the way into an era of regenerative medicine, in which damage from cancer, heart disease, and a host of other ailments can be healed with the body's own cells.

The process relies on naturally occurring regenerative cells. "What we have done," Calhoun says, "is developed products that allow a doctor to take a small amount of fat, the same volume as about half a can of Coke

MacroPore was from an investors viewpoint- kind of "the dark side" of Cytori- not only because of the failed Medtronic partnership on bio-resorbable implants, but also because of excessive option-plans and failed guidances on revenues etc. The preceeding article "History" was a more objective article and facts driven- what follows is surely also "facts driven", but has definitely a more subjective colour, in view of unrealized potential of the technology that Cytori possesses ( Icall it the "regenerative goldmine"), which potential has not been monetized by the management by any reasonable measurement yardstick sofar- the least as per the present stock price at the end of 2011 of somewhere around 2$.

On this spring afternoon, the 44-year-old CEO of San Diego- based biotech company Cytori Therapeutics pulls out his laptop, launches a PowerPoint presentation, and there they are: conical and cantaloupy. As through Ds, beige and pink and taupe and tan, more breasts than you might see in a women's locker room, never mind in the middle of a lunch table.

A passing waiter does a double take at this lively slide show, but Calhoun is oblivi­ous. He's talking excitedly about how these women's bodies led him and his team of sci­entists to a discovery in tissue engineer­ing, a process that could well be one of the most momentous medical advances of the 21st century: the use of stemcells..... specifically stem-cell enriched adipose (fat) tissue—to enhance, heal, and rebuild injured or damaged organs.

Part II- "These things have gone through the ringer in choosing a name," says biomechan-ical engineer Kent Leach of UC Davis, who has used whatever-they-are to treat bone cysts in racehorses. A stem cell, by definition, is able to differentiate into any of the 200-plus kinds of cells in the human body, just as the cells of a days-old embryo can (and do). Cytori's are unlikely to ever show that range of differentiation. But they can differentiate into fat, bone, and muscle -among other tissues—depending on which signaling molecules they are exposed to. In a petri dish, the scientists provide those "this is what you will be when you grow up" molecules. In nature—that is, an embryo in a womb—biology somehow does.

The management Team Of Cytori.

Christopher J. Calhoun is a co-founder of Cytori Therapeutics and has served as the Company's Chief Executive Officer, Vice-Chairman and Director of the Board since 1997.

He previously served as President from 1996 through 1998. Mr. Calhoun is the co-inventor on multiple U.S.

and International patents for medical devices and implant instrumentation. Mr. Calhoun was also involved in research and management for the Plastic Surgery Bone Histology and Histometry Laboratory at the University of California, San Diego.

Mr. Calhoun is a co-founder and Chairman of the Board of Leonardo MD, and has previously served on the Board of Directors of StemSource, Inc. Mr. Calhoun received a B.A. from the University of California, San Diego and an M.B.A. from the University of Phoenix.